Ann Pharmacother:加压素促酸中毒心肺骤停自主循环

2014-06-27 紫夕 医学论坛网

呼吸与代谢酸中毒时,肾上腺素的血管收缩作用迟钝,但对加压素的反应保持不变。这种作用对高级生命支持(ACLS)的影响尚未明确。美国学者研究发现,加压素联合肾上腺素治疗与单独使用肾上腺素治疗相比,能提高动脉血pH<7.2的心搏骤停患者自主循环(ROSC)比例,但出院存活率无差别。论文2014年5月在线发表于《药物治疗学年鉴》(Ann Pharmacother)。  &nbsp

呼吸与代谢酸中毒时,肾上腺素的血管收缩作用迟钝,但对加压素的反应保持不变。这种作用对高级生命支持(ACLS)的影响尚未明确。美国学者研究发现,加压素联合肾上腺素治疗与单独使用肾上腺素治疗相比,能提高动脉血pH<7.2的心搏骤停患者自主循环(ROSC)比例,但出院存活率无差别。论文2014年5月在线发表于《药物治疗学年鉴》(Ann Pharmacother)。
        

该研究旨在确定加压素联合肾上腺素治疗是否比单独使用肾上腺素更能改善心脏骤停患者的预后。主要结果是ROSC恢复率的不同。次要结果包括评估初始pH<7.2以及初始无脉搏节奏患者的ROSC比例。
        
研究为单一中心、回顾性研究,时间为2010年7月至2012年7月。纳入研究的患者年龄≥18岁,证明有过心搏骤停,需要进行ACLS和血管加压治疗。
        
结果为,共有101名患者满足纳入标准。接受加压素联合肾上腺素治疗的患者(n=43)与单独使用肾上腺素治疗的患者(n=58)相比,ROSC比例无差别(56% 对 60%,P=0.68),出院存活率也没有差别(9% 对 5%,P=0.46)。对于动脉血PH<7.2的患者亚组,ROSC分析结果显示,加压素联合肾上腺素治疗组比单独使用肾上腺治疗组的ROSC比例升高(63% 对 37%,P=0.01)。根据初始心搏节律进行亚组分析,结果显示ROSC比例无差别。

原始出处:

Barnes T1, Yan S2, Kaakeh Y3.Necrotizing Esophagitis and Bleeding Associated With Cefazolin: Case Report and Review of the Literature.Ann Pharmacother. 2014 May 20. pii: 1060028014537038. [Epub ahead of print]

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1787150, encodeId=05781e87150aa, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Tue Nov 18 05:52:00 CST 2014, time=2014-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908169, encodeId=f297190816949, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Mar 19 09:52:00 CST 2015, time=2015-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1684385, encodeId=4b4d16843850a, content=<a href='/topic/show?id=dfae5133e1d' target=_blank style='color:#2F92EE;'>#心肺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51337, encryptionId=dfae5133e1d, topicName=心肺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8e128082444, createdName=aids222, createdTime=Thu Dec 18 18:52:00 CST 2014, time=2014-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992038, encodeId=b7191992038a9, content=<a href='/topic/show?id=11b13296e8e' target=_blank style='color:#2F92EE;'>#加压素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32967, encryptionId=11b13296e8e, topicName=加压素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Mon Sep 08 20:52:00 CST 2014, time=2014-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1676121, encodeId=672316e61217b, content=<a href='/topic/show?id=6bac955861e' target=_blank style='color:#2F92EE;'>#酸中毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95586, encryptionId=6bac955861e, topicName=酸中毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5dd27335710, createdName=hywen7335, createdTime=Wed Mar 04 21:52:00 CST 2015, time=2015-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995902, encodeId=c5cf1995902dd, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Oct 17 12:52:00 CST 2014, time=2014-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318986, encodeId=ea9813189867f, content=<a href='/topic/show?id=14d92231508' target=_blank style='color:#2F92EE;'>#中毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22315, encryptionId=14d92231508, topicName=中毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Sun Jun 29 06:52:00 CST 2014, time=2014-06-29, status=1, ipAttribution=)]
    2014-11-18 jj000001
  2. [GetPortalCommentsPageByObjectIdResponse(id=1787150, encodeId=05781e87150aa, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Tue Nov 18 05:52:00 CST 2014, time=2014-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908169, encodeId=f297190816949, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Mar 19 09:52:00 CST 2015, time=2015-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1684385, encodeId=4b4d16843850a, content=<a href='/topic/show?id=dfae5133e1d' target=_blank style='color:#2F92EE;'>#心肺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51337, encryptionId=dfae5133e1d, topicName=心肺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8e128082444, createdName=aids222, createdTime=Thu Dec 18 18:52:00 CST 2014, time=2014-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992038, encodeId=b7191992038a9, content=<a href='/topic/show?id=11b13296e8e' target=_blank style='color:#2F92EE;'>#加压素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32967, encryptionId=11b13296e8e, topicName=加压素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Mon Sep 08 20:52:00 CST 2014, time=2014-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1676121, encodeId=672316e61217b, content=<a href='/topic/show?id=6bac955861e' target=_blank style='color:#2F92EE;'>#酸中毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95586, encryptionId=6bac955861e, topicName=酸中毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5dd27335710, createdName=hywen7335, createdTime=Wed Mar 04 21:52:00 CST 2015, time=2015-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995902, encodeId=c5cf1995902dd, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Oct 17 12:52:00 CST 2014, time=2014-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318986, encodeId=ea9813189867f, content=<a href='/topic/show?id=14d92231508' target=_blank style='color:#2F92EE;'>#中毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22315, encryptionId=14d92231508, topicName=中毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Sun Jun 29 06:52:00 CST 2014, time=2014-06-29, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1787150, encodeId=05781e87150aa, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Tue Nov 18 05:52:00 CST 2014, time=2014-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908169, encodeId=f297190816949, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Mar 19 09:52:00 CST 2015, time=2015-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1684385, encodeId=4b4d16843850a, content=<a href='/topic/show?id=dfae5133e1d' target=_blank style='color:#2F92EE;'>#心肺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51337, encryptionId=dfae5133e1d, topicName=心肺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8e128082444, createdName=aids222, createdTime=Thu Dec 18 18:52:00 CST 2014, time=2014-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992038, encodeId=b7191992038a9, content=<a href='/topic/show?id=11b13296e8e' target=_blank style='color:#2F92EE;'>#加压素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32967, encryptionId=11b13296e8e, topicName=加压素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Mon Sep 08 20:52:00 CST 2014, time=2014-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1676121, encodeId=672316e61217b, content=<a href='/topic/show?id=6bac955861e' target=_blank style='color:#2F92EE;'>#酸中毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95586, encryptionId=6bac955861e, topicName=酸中毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5dd27335710, createdName=hywen7335, createdTime=Wed Mar 04 21:52:00 CST 2015, time=2015-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995902, encodeId=c5cf1995902dd, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Oct 17 12:52:00 CST 2014, time=2014-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318986, encodeId=ea9813189867f, content=<a href='/topic/show?id=14d92231508' target=_blank style='color:#2F92EE;'>#中毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22315, encryptionId=14d92231508, topicName=中毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Sun Jun 29 06:52:00 CST 2014, time=2014-06-29, status=1, ipAttribution=)]
    2014-12-18 aids222
  4. [GetPortalCommentsPageByObjectIdResponse(id=1787150, encodeId=05781e87150aa, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Tue Nov 18 05:52:00 CST 2014, time=2014-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908169, encodeId=f297190816949, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Mar 19 09:52:00 CST 2015, time=2015-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1684385, encodeId=4b4d16843850a, content=<a href='/topic/show?id=dfae5133e1d' target=_blank style='color:#2F92EE;'>#心肺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51337, encryptionId=dfae5133e1d, topicName=心肺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8e128082444, createdName=aids222, createdTime=Thu Dec 18 18:52:00 CST 2014, time=2014-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992038, encodeId=b7191992038a9, content=<a href='/topic/show?id=11b13296e8e' target=_blank style='color:#2F92EE;'>#加压素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32967, encryptionId=11b13296e8e, topicName=加压素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Mon Sep 08 20:52:00 CST 2014, time=2014-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1676121, encodeId=672316e61217b, content=<a href='/topic/show?id=6bac955861e' target=_blank style='color:#2F92EE;'>#酸中毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95586, encryptionId=6bac955861e, topicName=酸中毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5dd27335710, createdName=hywen7335, createdTime=Wed Mar 04 21:52:00 CST 2015, time=2015-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995902, encodeId=c5cf1995902dd, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Oct 17 12:52:00 CST 2014, time=2014-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318986, encodeId=ea9813189867f, content=<a href='/topic/show?id=14d92231508' target=_blank style='color:#2F92EE;'>#中毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22315, encryptionId=14d92231508, topicName=中毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Sun Jun 29 06:52:00 CST 2014, time=2014-06-29, status=1, ipAttribution=)]
    2014-09-08 fyxzlh
  5. [GetPortalCommentsPageByObjectIdResponse(id=1787150, encodeId=05781e87150aa, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Tue Nov 18 05:52:00 CST 2014, time=2014-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908169, encodeId=f297190816949, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Mar 19 09:52:00 CST 2015, time=2015-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1684385, encodeId=4b4d16843850a, content=<a href='/topic/show?id=dfae5133e1d' target=_blank style='color:#2F92EE;'>#心肺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51337, encryptionId=dfae5133e1d, topicName=心肺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8e128082444, createdName=aids222, createdTime=Thu Dec 18 18:52:00 CST 2014, time=2014-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992038, encodeId=b7191992038a9, content=<a href='/topic/show?id=11b13296e8e' target=_blank style='color:#2F92EE;'>#加压素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32967, encryptionId=11b13296e8e, topicName=加压素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Mon Sep 08 20:52:00 CST 2014, time=2014-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1676121, encodeId=672316e61217b, content=<a href='/topic/show?id=6bac955861e' target=_blank style='color:#2F92EE;'>#酸中毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95586, encryptionId=6bac955861e, topicName=酸中毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5dd27335710, createdName=hywen7335, createdTime=Wed Mar 04 21:52:00 CST 2015, time=2015-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995902, encodeId=c5cf1995902dd, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Oct 17 12:52:00 CST 2014, time=2014-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318986, encodeId=ea9813189867f, content=<a href='/topic/show?id=14d92231508' target=_blank style='color:#2F92EE;'>#中毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22315, encryptionId=14d92231508, topicName=中毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Sun Jun 29 06:52:00 CST 2014, time=2014-06-29, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1787150, encodeId=05781e87150aa, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Tue Nov 18 05:52:00 CST 2014, time=2014-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908169, encodeId=f297190816949, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Mar 19 09:52:00 CST 2015, time=2015-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1684385, encodeId=4b4d16843850a, content=<a href='/topic/show?id=dfae5133e1d' target=_blank style='color:#2F92EE;'>#心肺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51337, encryptionId=dfae5133e1d, topicName=心肺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8e128082444, createdName=aids222, createdTime=Thu Dec 18 18:52:00 CST 2014, time=2014-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992038, encodeId=b7191992038a9, content=<a href='/topic/show?id=11b13296e8e' target=_blank style='color:#2F92EE;'>#加压素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32967, encryptionId=11b13296e8e, topicName=加压素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Mon Sep 08 20:52:00 CST 2014, time=2014-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1676121, encodeId=672316e61217b, content=<a href='/topic/show?id=6bac955861e' target=_blank style='color:#2F92EE;'>#酸中毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95586, encryptionId=6bac955861e, topicName=酸中毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5dd27335710, createdName=hywen7335, createdTime=Wed Mar 04 21:52:00 CST 2015, time=2015-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995902, encodeId=c5cf1995902dd, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Oct 17 12:52:00 CST 2014, time=2014-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318986, encodeId=ea9813189867f, content=<a href='/topic/show?id=14d92231508' target=_blank style='color:#2F92EE;'>#中毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22315, encryptionId=14d92231508, topicName=中毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Sun Jun 29 06:52:00 CST 2014, time=2014-06-29, status=1, ipAttribution=)]
    2014-10-17 yb6560
  7. [GetPortalCommentsPageByObjectIdResponse(id=1787150, encodeId=05781e87150aa, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Tue Nov 18 05:52:00 CST 2014, time=2014-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908169, encodeId=f297190816949, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Mar 19 09:52:00 CST 2015, time=2015-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1684385, encodeId=4b4d16843850a, content=<a href='/topic/show?id=dfae5133e1d' target=_blank style='color:#2F92EE;'>#心肺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51337, encryptionId=dfae5133e1d, topicName=心肺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8e128082444, createdName=aids222, createdTime=Thu Dec 18 18:52:00 CST 2014, time=2014-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992038, encodeId=b7191992038a9, content=<a href='/topic/show?id=11b13296e8e' target=_blank style='color:#2F92EE;'>#加压素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32967, encryptionId=11b13296e8e, topicName=加压素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Mon Sep 08 20:52:00 CST 2014, time=2014-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1676121, encodeId=672316e61217b, content=<a href='/topic/show?id=6bac955861e' target=_blank style='color:#2F92EE;'>#酸中毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95586, encryptionId=6bac955861e, topicName=酸中毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5dd27335710, createdName=hywen7335, createdTime=Wed Mar 04 21:52:00 CST 2015, time=2015-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995902, encodeId=c5cf1995902dd, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Oct 17 12:52:00 CST 2014, time=2014-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318986, encodeId=ea9813189867f, content=<a href='/topic/show?id=14d92231508' target=_blank style='color:#2F92EE;'>#中毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22315, encryptionId=14d92231508, topicName=中毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Sun Jun 29 06:52:00 CST 2014, time=2014-06-29, status=1, ipAttribution=)]
    2014-06-29 mashirong

相关资讯

JAMA:加压素-肾上腺素联用可改善心搏骤停患者出院生存

希腊一项研究表明,在需血管升压药治疗的心搏骤停患者中,心肺复苏(CRP)期间联合应用加压素-肾上腺素以及复苏后休克中应用氢化可的松可改善神经转归良好的出院生存率。论文发表于《美国医学会杂志》[JAMA.2013;310(3):270]。 此项随机双盲安慰剂对照研究共纳入268例依据复苏指南需肾上腺素治疗的心搏骤停患者,并在前5个CRP周期给予加压素联合肾上腺素(VSE组,n = 130)或生理盐